Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Nematicide is a type ... are microscopic parasitic roundworms, found in massive quantities ... plants and animals. Nematicides have tended to be ... promoting migration through the soil. A single gram ... nematodes. With more than 10,000 species classified, they ...
(Date:9/30/2014)... September 30, 2014 Follow us ... of each type of cholesterol carrier or lipoprotein in ... of excessive cholesterol levels in the body, especially along ... to heart attack and other cardiovascular disorders. Cardiovascular Diseases ... testing for cholesterol levels on a regular basis, to ...
(Date:9/30/2014)... BUDAPEST, Hungary , September 30, 2014 /PRNewswire/ ... libraries and intuitive browsing of chemistry in documents ... providing chemistry software solutions and consulting services for ... extract chemical information and generate Markush structures from ... securing an organizations intellectual property, however generating and ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... CXM ) and its operating unit InnerCool ... clearance from the U.S. Food and Drug,Administration (FDA) ... device. InnerCool,s RapidBlue System is a thermal,regulating system ... new system automatically cools or warms patients, as ...
... October,22, 2008, GlaxoSmithKline plc (NYSE: GSK ) will ... ended September 30, 2008. The,announcement is scheduled for release ... am EDT., At 10:00 am EDT, media are ... hosted by Andrew Witty, Chief Executive Officer,and Julian Heslop, ...
... the North Carolina Research Campus as its newest tenant partner. The ... Food Inc. Nine universities and colleges (including Duke University, UNC, and ... North Carolina. The Campus promises to be a world class center ... ...
Cached Biology Technology:Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 2Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 3Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 4Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 5Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 6Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 7Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 8Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 9Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 10Food and Beverage Giant Joins Kannapolis Research Center 2Food and Beverage Giant Joins Kannapolis Research Center 3Food and Beverage Giant Joins Kannapolis Research Center 4
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... German . , ... situations such as exposure to predators. Researchers from the ... long-term study on different populations of great tits that ... temperature. High metabolic rates and low temperatures were associated ... were more likely to approach potential predators. , The ...
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... , WEST LAFAYETTE, Ind. - Warmer, drier summers and ... would be especially troublesome - possibly fatal - for ... Over five years, Douglass Jacobs, a professor of forestry ... student under Jacobs who is now a research scientist ...
... colonies worldwide suffering mysterious deaths? A unique study describes a ... a major economic challenge. Honey bees are the ... to food production. Honey bee health is a ... colonies in the USA and Europe. Recently, the European Union ...
... world that her computer model of a key brain ... potential relevance to Parkinson,s disease, Stephanie Jones sought to ... now close collaborators, but when they first started talking ... Jones was plain wrong, if not a bit nuts. ...
Cached Biology News:Walnut trees may not be able to withstand climate change 2Honey bee mystery protein is a freight train for health and lifespan 2New study to test unusual hypothesis on beta brainwaves 2New study to test unusual hypothesis on beta brainwaves 3New study to test unusual hypothesis on beta brainwaves 4
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
... a comprehensive kinase analysis service utilizing ... peptide microarrays synthesized on Paraflo microfluidic ... quantitative measurement of kinase kinetic activities, ... service includes preparation of your kinase ...
... NH2-terminal kinase) signal transduction cascade is ... pathways in mammals. JNK pathway activation ... is associated with the nuclear accumulation ... in the immune response, cellular proliferation, ...
... ProteomeLab PA 800 is an automated, ... of Beckman Coulters ProteomeLab family of ... comprehensive range of automated protein characterization ... mapping, isoelectric focusing, carbohydrate profiling and ...
Biology Products: